Cellular therapy is a rapidly growing field with a high demand to define clinically and scientifically appropriate technology for cell propagation [1] . Attempts to develop protocols for ideally completely defined animal-and human serum-free clinical cell propagation have not been completely successful yet (for review [2] ). Human platelet lysate (HPL) has been used as a highly efficient substitute for fetal bovine serum (FBS) for preclinical cell propagation, most commonly used for mesenchymal and endothelial progenitors for more than a decade [3] [4] [5] [6] . The development of a good manufacturing practice (GMP)-grade HPL derived from released blood donations has become a key aspect for animal serum-free cell manufacturing, enabling applications in advanced somatic cell therapy and tissue engineering [7, 8] .
HPL is currently supposed to be the most promising human cell culture supplement replacing FBS in a growing number of applications. The current knowledge about HPL including details on donor selection, manufacturing and applicability for various human cell types has recently been summarized [3, 9] . At present, it is not possible to devise common recommendations for a standardization of HPL production, definitions of specifications and of release criteria to control the high variability in starting material characteristics, crucial preparation steps and quality, as well as functionality of the final product. From a clinical transfusion medicine perspective, the use of HPL for cell propagation goes far beyond collecting outdated platelets.
Whenever HPL use for the production of cell-based medicinal products is intended, we have to consider regulatory issues. As an ingredient of the culture medium, HPL has contact with the cells during in vitro propagation andalthough not intended -may become part of the final cell product at least at trace levels. In the last years, increasing efforts have been made by regulatory authorities to clarify the use of raw materials, named ancillary materials of biologic origin for the manufacture of cellular therapies in the United States. An elaborate overview of guidance on the use of raw materials by national and international organizations including the U.S. Food and Drug Administration (FDA), the International Standards Organization (ISO), the International Conference on Harmonization (ICH) and the European Medicines Agency (EMA) has been outlined in [10] . In general, there exist regulations for the manufacture of cell therapeutics but only few specific descriptions of quality requirements for raw and ancillary materials. The U.S. Pharmacopeia (USP <1043> [11] and USP <1046>
[12]) describes the qualification program for ancillary materials and provides tiers of sample risk categories as a guidance for risk analysis. Concerning the complex mixture of HPL constituents, the development of performance testing instead of identification and characterization is considered more suitable. Thus, it is recommended, as one example, to assess the functional attributes of ancillary materials by demonstrating the promotion of cell proliferation in a lot-to-lot comparison.
A new general chapter on 'Raw materials for the production of cell-based and gene therapy medicinal products' has been adopted in the framework of the last European Pharmacopoeia Commission session in 2015 and is now published in the 9th Edition of the European Pharmacopoeia [13], effective 1 January 2017. Notably, the chapter is for information only and not legally binding. To meet general quality requirements, raw materials must at least be predefined for the key parameters: identity, purity and biological activity. 'The impact of the raw material on the quality, safety and efficacy of the cellbased/gene therapy medicinal product is evaluated using a risk-based approach' and 'it is the responsibility of both the manufacturer and user of a raw material to qualify the raw material . . .' ([13] Chapter 5Á2Á12).
Motivated by the rapidly increasing demand for clinical grade HPL, we have invited experts in the field from several centres in Europe, the United States, Asia and Australia to declare their point of view with respect to their in-house manufacturing, performance of quality control, definition of release criteria and a future approach to standardization of HPL for this Vox Sanguinis International Forum.
The following questions were sent to the centres: • Question 1: Do you produce GMP-grade human platelet lysate (HPL) for expanding cells for clinical use based on a licence by your national authority?
• 
Summary of responses
We received answers to the questionnaire from 14 centres (EU = 10; Asia = 2; U.S.A = 1; Australia = 1). Tables 1-4 give an overview of the most relevant information provided by the centres. GMP-grade manufacturing of HPL is established in 7 centres (Tables 1 and 3 Helsinki (Finland), Ulm and T€ ubingen (Germany), Bergamo (Italy), Salamanca (Spain) and Salt Lake City (Utah, USA). One centre (Sydney, Australia) will be preparing for GMP-grade HPL production in the near future. The technology of HPL production for RUO is commonly the basis for GMP-grade production procedures in the future. We therefore also included the centres with RUO-HPL to present the current international status (Tables 2 and 4 ).
Manufacturing of HPL
All centres use standard platelet concentrates (PCs) derived from regular healthy blood donors after written informed consent and fulfilling the national and international regulatory issues as starting material. As these blood products are licensed for transfusion, the required screening of infectious disease markers has been performed and products tested negative. Furthermore, usually based on IT documentation, all donor data and manufacturing details are collected and stored, enabling the required traceability of HPL as a raw or ancillary material for the production of cell therapeutics. There is no clear preference for the use of single donor apheresis-or pooled buffy-coat-derived platelet concentrates (PCs) as starting material for GMP-grade HPL manufacture in the respective centres and no difference in the RUO-HPL centres. Six centres use pooled buffycoat-derived PCs, five centres use apheresis-and pooled buffy-coat-derived PCs, and one centre uses apheresisand platelet-rich-plasma-derived PCs. Only two centres exclusively use apheresis-derived PCs. Regarding the selection of PCs for GMP-HPL production, two centres exclusively use fresh PCs (Salzburg, Austria and Helsinki, Finland) and five centres use only expired PCs. Also in centres producing RUO-HPL, expired PCs are the predominant starting material. In both groups, some centres accept PCs treated routinely following irradiation or pathogen inactivation (Intercept TM Blood System). The latter is routinely performed in Innsbruck (Austria), Reykjavik (Iceland) and Salamanca (Spain).
The most common threshold for platelet concentration is indicated as 2 9 10 11 /PC unit. Notably, independent of GMP production, only four centres consider the match of ABO blood groups for pooling of lysates, reflecting current science regarding an influence of ABO antigens and isoagglutinins on biology and function of cultured cells. All GMP-HPL suppliers induce platelet lysis by one or more freeze-thaw cycles of PCs (-20 to -80°C and 37°C). As alternative lysis procedures, thrombin activation, CaCl 2 addition and solvent/detergent (S/D) treatment were reported by two RUO-HPL centres (Mannheim/Frankfurt, Germany and Taipei, Taiwan). The efficiency of lysis was not routinely validated by all participants.
Due to the inherent risk of transmission of pathogens, the European Pharmacopoeia ([13] Chapter 5Á2Á12) recommends to limit the number of pooled blood products '. . .unless sufficient methods for inactivation/removal of viruses are applied during production, where applicable.' In our questionnaire, all participating centres perform a pooling procedure for HPL to avoid donor variations, although even for GMP-grade manufacture the number of pooled lysates is highly variable (from 4 up to 125 PC units).
The physiological fibrinogen concentration in HPL derived from 100% plasma-containing PCs averages 1Á5-3 mg/mL [3] , requiring addition of heparin to the culture medium to avoid gel formation. As the influence of fibrinogen on the cultured cell's biology is still not clarified and heparin has been widely used therapeutically for many years, fibrinogen depletion is not a common manufacturing procedure. Of the seven centres with GMP-grade HPL production, only two centres (T€ ubingen, Germany and Salt Lake City, USA) routinely deplete fibrinogen, the latter by CaCl 2 addition resulting in serum-converted HPL. For research purposes, some centres perform CaCl 2 addition, passive clotting of HPL in the culture medium and fibrinogen removal or deplete the plasma itself completely. In most of the centres, a final centrifugation step to remove platelet fragments and sterile filtration of the HPL product is performed.
Stability, quality control and release criteria
As outlined previously [10] and according to the international regulations, HPL as raw or ancillary material should be qualified on the basis of five key attributes: source, purity, identity, safety and suitability. The grade of the qualification program is of course depending on the mode of application. Stability tests of HPL are required to define optimal storage conditions and shelf life. Notably, suppliers as well as users of HPL are responsible for assessing stability of HPL for intended application [10] . Four of the seven centres producing GMP-HPL have already validated HPL stability by cell proliferation assays and/or analysis of selected growth factor Defined thresholds for biochemical analyses. hMSC outgrowth: support confirmed.
hMSCs 5-10% HPL in the medium AT, adipose tissue; BM, bone marrow; hECFC, human endothelial colony-forming progenitor cells; GMP, Good Manufacturing Practice; hMSC, human mesenchymal stromal cells; HPL, human platelet lysate; PDGF, platelet-derived growth factor; UC, umbilical cord; UCB, umbilical cord blood; WBC, white blood cells. concentration. Consequently, HPL storage is recommended for maximum 2 years at -30°C and up to 5 years at -80°C. Three centres without in-house stability tests recommend a shelf life of maximum 12 months at -20 to -30°C (see also Table 3 ). Centres with RUO-HPL also have defined storage time and conditions between 5 months at -20°C and up to 2 years at -20 to -30°C (Table 4) .
For quality control, proof of sterility by exclusion of bacterial, mycoplasma and fungal contamination as well as endotoxin testing is routinely performed by almost all centres. Additionally, selected growth factor content, residual white blood cells, biochemical composition (e.g. haemoglobin, electrolytes, total protein, albumin, lipids, glucose and fibrinogen), isoagglutinin titres and parameters such as pH or osmolality may be estimated for each lot.
Like some other raw or ancillary materials, HPL is a highly complex mixture of substances and there is a risk of lot-to-lot variability. Furthermore, purity and identity cannot be easily defined due to a lack of suitable chemical or physical assays. For this reason, the U.S. Pharmacopeia (USP <1043>) recommends the development of performance assays simulating the expected functional attribute, for example support of cell proliferation. In this case, the assay should demonstrate that the new lot of HPL shows an at least acceptable proliferation rate of cultured cells in a parallel comparison with a reference lot [11] . Regarding our questionnaire, three of the GMP-HPL and three of the RUO-HPL centres have already established routine performance testing, all using human mesenchymal stromal cells (MSCs) as responder cells. Appropriate and centre-specific release criteria have been defined and/or are recommended (see also corresponding answers to Question 13 in the text) in accordance with the respective tested parameters (see Tables 3 and 4) .
As HPL has the potential to support proliferation of various human and animal-derived cell types [3] , we asked the centres for their spectrum of cell culture and usual concentration of HPL in the basal media (for details, see Tables 3 and 4) . Some of the centres already use GMP-HPL for manufacture of MSC therapeutics in ongoing clinical trials.
Consensus on a need for standardization of HPL?
Considering all reported variations of GMP-grade HPL manufacturing protocols, we are currently far from standardization. Individual technologies partially depend on national regulations and local availability of specific formulations of PCs used in the clinic. Additionally, limited resources may influence the decision to select expired instead of fresh PCs. The use of pathogen-inactivated and irradiated PCs is rather dependent on routine treatment of PCs than on an active decision during HPL manufacture.
All of the participating centres agreed, in principle, that HPL standardization is a necessary next step for the development and optimization of cell therapy and for fulfillment of regulatory requirements. A standardized nomenclature, defining source material and product specifications, will help to improve comparability of cell product quality and/or functionality in clinical trials. However, there is concern that HPL is a new and until now not a well-characterized product. Even basic parameters including the amount of essential growth factors, plasma-derived substances and other ingredients necessary for optimal culture of different cell types still have to be defined. Some centres recommend a comparison of differentially manufactured HPL products ideally in parallel performance assays with various cell types. This may enable the user to select the best HPL preparation for a specific cell product, considering not only cell proliferation but also cell functionality and potency. In detail, arguments were provided within the answers to Question 12.
Conclusion
The purpose of manufacturing GMP-grade HPL is its use as a raw or ancillary material for the production of cellbased medicinal products. Due to the direct contact of HPL with the cultured cells, it is a critical component at least regarding safety, purity and potency of the final cell product. We have to consider the various objectives of cell therapy leading to specific claims for cell potency and biological activity. HPL variability may influence product quality during manufacturing.
Under the aegis of national and international regulatory requirements, we will have to define HPL product specifications and standardized GMP-grade manufacturing protocols depending on the claims and specifications of the particular cell-based medicinal product.
